Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (Bla) With U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
capricor therapeutics宣佈已開始向美國FDA遞交生物製品許可申請(BLA)的滾動提交,用於治療杜興氏肌營養不良症。
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (Bla) With U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
capricor therapeutics宣佈已開始向美國FDA遞交生物製品許可申請(BLA)的滾動提交,用於治療杜興氏肌營養不良症。
譯文內容由第三人軟體翻譯。